Infectious Disease Point of Care Testing to Grow at 8% Rate, Predicts GlobalData in Its Report Published at MarketPublishers.com
29 Nov 2016 • by Natalie Aster
LONDON – At present, the infection disease POCT forms one of the most rapidly growing segments of the POCT marketplace. It enjoys annual sales of approximately USD 700 million globally. It is expected to grow at a CAGR of around 8% in the offing. Brazil, the U.S. and India are likely to become major contributors to the growth.
This growth will be ignited by such factors as the rising prevalence of infectious diseases across developing countries, the test menu expansion, the rising demand for home-based POC devices, and more.
There are quite many players in this market, and Alere, Cepheid, Quidel and Trinity Biotech are some of those that take the lead.
In-demand research report “MediPoint: Infectious Disease Point of Care Testing - Global Analysis and Market Forecasts” prepared by GlobalData is a source of the valuable and the most recent information on the world’s infectious disease POC marketplace. The study starts with a thorough overview of the industry.
It covers reimbursement trends in different countries: the U.S., Germany, Spain, India, China, Brazil, to name just a few. The report unveils unmet needs and proceeds with the competitive assessment of the worldwide space.
The research study comprises the pipeline assessment, as well. It proceeds with a detailed market outlook by exploring test trends, shedding light on this market’s dynamics and investigating key regions. Global forecasts are on hand in the research report, too.
Reasons to Buy:
- get access to the most recent information of the global infectious disease POC space;
- find out which trends shape this marketplace;
- learn key trends of the market;
- gain understanding of the competitive environment;
- see which companies may take the lead in the offing;
- get valuable sales statistics (with historical and forecast data included).
More cutting-edge studies by GlobalData are available at its page.